B Ubrig1, M Böhme2, A Merklinghaus3, F Wagenlehner4. 1. Klinik für Urologie, , Augusta-Kranken-Anstalt gGmbH, Bergstr. 26, 44791, Bochum, Deutschland. ubrig@augusta-bochum.de. 2. Gemeinschaftspraxis für Urologie, Bochum-Wattenscheid, Bochum, Deutschland. 3. Klinik für Urologie, , Augusta-Kranken-Anstalt gGmbH, Bergstr. 26, 44791, Bochum, Deutschland. 4. Lehrstuhl für Urologie, Kinderurologie und Andrologie, Justus Liebig Universität Gießen, Gießen, Deutschland.
Abstract
BACKGROUND: Published studies on community-acquired urinary tract infections (UTI) often do not link microbiological findings with clinical risk factors and patient data. MATERIALS AND METHODS: We retrospectively correlated clinical findings of all patients with UTI of a urological outpatient clinic with the respective microbiological analysis of their urine samples over 2 periods of time: (A: 2005-2006 and B: 2011-2012). Patients were stratified to the following risk groups: uncomplicated cystitis, diabetes mellitus type 2, nursing home resident, prostatitis/epidydimitis, permanent catheter. RESULTS: The incidence of Escherichia coli (p < 0.001) and proteus (p < 0.001) significantly decreased from period A to B, while enterococci (p = 0.003) and staphylococci (p < 0.001) significantly increased. Antibiotic sensitivity to fosfomycin (p < 0.001), doxycycline (p < 0.001), nitrofurantoin (p < 0.001), and nitroxoline increased (p < 0. 001) and sensitivity to amoxicillin (p < 0.001) and gentamicin decreased (p < 0.001). Patients with a permanent catheter had significantly poorer sensitivity rates (50% and less) for almost all antibiotics tested compared to the overall group. The risk of a UTI with 3MRGN or MRSA bacteria was significantly higher for catheter carriers and nursing home residents. CONCLUSIONS: Empiric antibiotic first-line therapy with nitrofurantoin and fosfomycin for uncomplicated community acquired UTIs are well indicated in conformity with guidelines. The accumulation of multiresistant pathogens in patients with a permanent bladder catheter requires restrictive use of any permanent catheter drainage.
BACKGROUND: Published studies on community-acquired urinary tract infections (UTI) often do not link microbiological findings with clinical risk factors and patient data. MATERIALS AND METHODS: We retrospectively correlated clinical findings of all patients with UTI of a urological outpatient clinic with the respective microbiological analysis of their urine samples over 2 periods of time: (A: 2005-2006 and B: 2011-2012). Patients were stratified to the following risk groups: uncomplicated cystitis, diabetes mellitus type 2, nursing home resident, prostatitis/epidydimitis, permanent catheter. RESULTS: The incidence of Escherichia coli (p < 0.001) and proteus (p < 0.001) significantly decreased from period A to B, while enterococci (p = 0.003) and staphylococci (p < 0.001) significantly increased. Antibiotic sensitivity to fosfomycin (p < 0.001), doxycycline (p < 0.001), nitrofurantoin (p < 0.001), and nitroxoline increased (p < 0. 001) and sensitivity to amoxicillin (p < 0.001) and gentamicin decreased (p < 0.001). Patients with a permanent catheter had significantly poorer sensitivity rates (50% and less) for almost all antibiotics tested compared to the overall group. The risk of a UTI with 3MRGN or MRSA bacteria was significantly higher for catheter carriers and nursing home residents. CONCLUSIONS: Empiric antibiotic first-line therapy with nitrofurantoin and fosfomycin for uncomplicated community acquired UTIs are well indicated in conformity with guidelines. The accumulation of multiresistant pathogens in patients with a permanent bladder catheter requires restrictive use of any permanent catheter drainage.
Authors: Naomi S Baldwin; Deirdre F Gilpin; Carmel M Hughes; Mary P Kearney; D Ann Gardiner; Chris Cardwell; Michael M Tunney Journal: J Am Geriatr Soc Date: 2009-04 Impact factor: 5.562
Authors: F M E Wagenlehner; Mete Cek; Kurt G Naber; Hiroshi Kiyota; Truls E Bjerklund-Johansen Journal: World J Urol Date: 2011-09-07 Impact factor: 4.226
Authors: I G Baraboutis; E P Tsagalou; J L Lepinski; I Papakonstantinou; V Papastamopoulos; A T Skoutelis; S Johnson Journal: Eur J Clin Microbiol Infect Dis Date: 2010-05-30 Impact factor: 3.267
Authors: P Cassier; S Lallechère; S Aho; K Astruc; C Neuwirth; L Piroth; P Chavanet Journal: Clin Microbiol Infect Date: 2011-04-12 Impact factor: 8.067
Authors: Florian M E Wagenlehner; Fabian Münch; Adrian Pilatz; Birte Bärmann; Wolfgang Weidner; Christine M Wagenlehner; Marion Straubinger; Holger Blenk; Wolfgang Pfister; Michael Kresken; Kurt G Naber Journal: Antimicrob Agents Chemother Date: 2013-11-11 Impact factor: 5.191
Authors: P Brugnaro; U Fedeli; G Pellizzer; D Buonfrate; M Rassu; C Boldrin; S G Parisi; A Grossato; G Palù; P Spolaore Journal: Infection Date: 2008-12-09 Impact factor: 3.553